Vertex Pharmaceuticals (VRTX) Institutional Ownership
13F filers reported holding 12.6% of Vertex Pharmaceuticals (VRTX) shares as of Sep 30, 2026, across 1,069 filers.
- Held by 13F filers
- 12.6%
- Sep 30, 2026
- 13F filers
- 1,069
- quarter ended Sep 30, 2026
- 13F value
- $16.7B
- 31.9M shares
- Quarter's fund flow
- Mild accumulation
- 94 new · 47 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Oct 20, 2026 | Brennan Daniel J. | director | Acquired · Grant / award | 795 | $503.47 | ↗ |
| Oct 15, 2026 | SACHS BRUCE I | director | Acquired · Grant / award | 93Deferred Stock Units | $512.44 | ↗ |
| Oct 15, 2026 | Garber Alan M | director | Acquired · Grant / award | 29Deferred Stock Units | $512.44 | ↗ |
| Sep 8, 2026 | van Grunsven Jasper | EVP, CP and NPPO | Acquired · Grant / award | 8,682 | — | ↗ |
| Aug 28, 2026 | Ambrose Kristen | SVP & Chief Accounting Officer | Acquired · Grant / award | 5,000 | — | ↗ |
| Jul 21, 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Acquired · Grant / award | 8,251 | — | ↗ |
| Jul 21, 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Acquired · Grant / award | 8,251 | — | ↗ |
| Jul 15, 2026 | SACHS BRUCE I | director | Acquired · Grant / award | 100Deferred Stock Units | $475.28 | ↗ |
| Jul 15, 2026 | Garber Alan M | director | Acquired · Grant / award | 32Deferred Stock Units | $475.28 | ↗ |
| Jul 2, 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Disposed · Open-market sale | 1,500 | $524.99 | ↗ |
| Jul 2, 2026 | McKechnie Duncan | EVP, Chief Commercial Officer | Disposed · Open-market sale | 1,541 | $519.00 | ↗ |
| Jul 1, 2026 | Liu Joy | EVP and Chief Legal Officer | Disposed · Open-market sale | 828 | $502.71 | ↗ |
| Jun 26, 2026 | Bozic Carmen | EVP and CMO | Disposed · Open-market sale | 596 | $482.50 | ↗ |
| Jun 18, 2026 | Bozic Carmen | EVP and CMO | Disposed · Open-market sale | 1,020 | $462.17 | ↗ |
| Jun 15, 2026 | Bozic Carmen | EVP and CMO | Disposed · Open-market sale | 4,062 | $450.00 | ↗ |
| Jun 5, 2026 | Bozic Carmen | EVP and CMO | Disposed · Open-market sale | 1,745 | $450.00 | ↗ |
| Jun 1, 2026 | Liu Joy | EVP and Chief Legal Officer | Disposed · Open-market sale | 828 | $439.91 | ↗ |
| May 29, 2026 | Bozic Carmen | EVP and CMO | Disposed · Open-market sale | 1,974 | $450.00 | ↗ |
| May 15, 2026 | Bunnage Mark E. | EVP, Chief Scientific Officer | Disposed · Open-market sale | 33 | $453.45 | ↗ |
| May 15, 2026 | Bozic Carmen | EVP and CMO | Disposed · Open-market sale | 1,354 | $453.45 | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Vertex Pharmaceuticals do institutions hold?
13F filers reported holding 12.6% of Vertex Pharmaceuticals' shares as of Sep 30, 2026, across 1,069 filers.
How many 13F filers hold Vertex Pharmaceuticals?
Vertex Pharmaceuticals was held by 1,069 13F filers as of Sep 30, 2026.
Not investment advice.

